Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Megestrol acetate and olanzapine for malnutrition in cancer patients receiving immunotherapy
NCT06500234Phase 3Recruiting
- Sponsor
- Affiliated Qingdao Central Hospital of Qingdao University
- Start
- Jun 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of megestrol and olanzapine in cancer (2 arms), sponsored by Affiliated Qingdao Central Hospital of Qingdao University. Primary endpoint: Objective Response Rate at 12 months. Started Jun 2024; status: recruiting.
02
Drugs
megestrololanzapine
03
Conditions
cancer
Beyond the preview
Go deeper on NCT06500234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06500234.